NEWS

Press Releases

Media Coverage

Additional Partnerships

12/10/2020
- Genomic Sequencing
Bayer and Tempus Initiate Collaboration to Advance Patient Access to Genomic Testing and Precision Medicine

Bayer and Tempus, leaders in precision medicine and artificial intelligence (AI), announced a new collaboration designed to provide broader access to genomic testing and tailored treatment approaches for the oncology community. The collaboration will include an initiative to help facilitate patient identification for precision oncology by providing testing, via the Te...
11/24/2020
Tempus CE Marks Its Broad-Panel Genomic Sequencing Test, xT

Tempus, a leader in artificial intelligence and precision medicine, today announced that it has CE marked its signature broad-panel genomic sequencing assay, xT. The CE marked xT test is now available for clinical use in Europe. As part of Tempus’ broader regulatory strategy, European clinicians and their patients...
06/22/2020
- Genomic Sequencing
- Neuro/Psych
Tempus Announces Christopher Mason, PhD, Joins as Vice President of Emerging Genome Technology

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that Christopher Mason, PhD, has joined as the Vice President of Emerging Genome Technology. Dr. Mason has been a pioneer in next-generation sequencing (NGS) diagnostics, multi-omic approaches to modeling disease,...
06/01/2020
- Clinical Trials
- Genomic Sequencing
Tempus Launches Prospective “Priority” Research Study and Increases Support for Oncology Research Initiatives Despite Pandemic Challenges

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announces its study, along with a collaborative research initiative to expedite project needs during the COVID-19 pandemic. Many oncology research projects have been delayed as building the necessary datasets are difficult...
05/31/2020
Tempus Launches New Precision Medicine-Driven Tests: Tempus|HRD and Tempus|TO

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announced the launch of two new oncology tests designed to equip physicians with even more precise genomic data in an effort to improve therapeutic outcomes. Tempus|HRD, a test that identifies a...
05/29/2020
- Clinical Trials
- Genomic Sequencing
Tempus TIME Trial™ Program Reaches Critical Scale and Operational Milestones

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, has reached a milestone in fully enrolling 2,500 oncologists into its Tempus Integrated Molecular Evaluation (TIME) Trial™ Program that seeks to rapidly match patients largely in the community setting to targeted clinical trials....
02/03/2020
- Clinical Trials
- Genomic Sequencing
New Genomics Technology Puts Precision Oncology into Practice at Rush

Rush University Medical Center is the first health care organization to launch medical record company Epic’s module for genomic results, giving providers the tools they need to tailor patient care at the molecular level. Rush will use the module as part of its Precision Oncology Center to...
01/20/2020
- Cardiology
- Genomic Sequencing
Tempus Unveils AI-Enabled Smart Tests Across Disease Types

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, unveils its AI-enabled laboratory test (smart test) platform. Through its technology, laboratory tests are now able to be embedded with real-world evidence that deliver real-time, actionable insights to physicians, providing critical information...
01/15/2020
- Genomic Sequencing
Tempus Announces the Addition of Ari Caroline and Iker Huerga To Its Leadership Team

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announces the appointment of Ari Caroline and Iker Huerga as the Senior Vice President of Health Strategy and Vice President of Data Engineering and Strategy, respectively. Caroline and Huerga have joined Tempus...
12/12/2019
CVS Health Launches Transform Oncology Care™ Program to Help Improve Patient Outcomes and Lower Overall Costs

CVS Health (NYSE: CVS) today announced Transform Oncology Care™, anchored on a first-of-its-kind precision medicine strategy for payors. The program uses genomic testing results at the point-of-prescribing to help patients start on the best treatment, faster and in addition, matches eligible patients to clinical trials. Transform Oncology Care...

1 2 3 4 5 6 7 8 9